Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

被引：24
|
作者：
Valle, JW
Dangoor, A
Beech, J
Sherlock, DJ
Lee, SM
Scarffe, JH
Swindell, R
Ranson, M
机构：
[1] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[2] N Manchester Grp Hosp, Pennine Acute Hosp NHS Trust, Manchester M8 5RB, Lancs, England
[3] Middlesex Hosp, London W1T 3AA, England
[4] Lister Hosp, E&N Herts NHS Trust, Stevenage SG1 4AB, Herts, England
来源：
BRITISH JOURNAL OF CANCER | 2005年 / 92卷 / 04期
关键词：
pegylated liposomal doxorubicin; hepatocellular carcinoma; phase II;
D O I：
10.1038/sj.bjc.6602394
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(-2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.
引用
收藏
页码：628 / 630
页数：3
相关论文
共 50 条
  • [21] Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study
    Leonardi, Vita
    Palmisano, Valentina
    Pepe, Alessio
    Usset, Antonella
    Manuguerra, Giovanna
    Savio, Giuseppina
    De Bella, Manuela Tamburo
    Laudani, Agata
    Alu, Massimo
    Cusimano, Maria Pia
    Scianna, Caterina
    Giresi, Armando
    Agostara, Biagio
    ONCOLOGY LETTERS, 2010, 1 (04) : 749 - 753
  • [22] Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer
    Vergote, I. B.
    Colombo, N.
    Kutarska, E.
    Del Campo, J.
    Pippitt, C.
    Casado, A.
    Lengyel, E.
    Gilder, K.
    Ho, S.
    Schilder, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in metastatic breast cancer (MBC) patients: A phase II study.
    Fabi, A
    Papaldo, P
    Ciccarese, M
    Salesi, N
    Lorusso, V
    Ferretti, G
    Carlini, P
    Sacchi, I
    Cecere, F
    Cognetti, F
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 80S - 80S
  • [24] Phase II study of pegylated liposomal doxorubicin (PLD) and oxaliplatin (L-OHP) in recurrent ovarian cancer (ROC)
    Recchia, Francesco
    Saggio, Gaetano
    Amiconi, Giovanna
    Di Blasio, Anna
    Cesta, Alisia
    Candeloro, Giampiero
    Carta, Gaspare
    Rea, Silvio
    ANNALS OF ONCOLOGY, 2006, 17 : 171 - 171
  • [25] Pegylated liposomal doxorubicin hydrochloride (PLD) for advanced sarcomas in children:: Preliminary results
    Muñoz, A
    Maldonado, M
    Pardo, N
    Fernández, JM
    Vela, E
    Cubells, J
    PEDIATRIC BLOOD & CANCER, 2004, 43 (02) : 152 - 155
  • [26] Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma
    Lind, Pehr A.
    Naucler, Gisela
    Holm, Agneta
    Gubanski, Michael
    Svensson, Christer
    ACTA ONCOLOGICA, 2007, 46 (02) : 230 - 233
  • [27] A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma
    Valerio, MR
    Tagliaferri, P
    Raspagliesi, F
    Fulfaro, F
    Badalamenti, G
    Arcara, C
    Cicero, G
    Russo, A
    Venuta, S
    Guarneri, G
    Gebbia, N
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 : 79 - 85
  • [28] A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results
    Street, Daron G.
    Kuttschreuter, Luke
    Starks, David
    Mahdi, Haider
    Linn, Carlos
    Pavlov, Dmitri
    Peguero, Julio Antonio
    Chawla, Sant P.
    Bruns, Ingmar
    Waggoner, Steven E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Pegylated liposomal doxorubicin (PLD) combined with trabectedin as a treatment option in uterine sarcomas
    Strobel, L.
    Steinlechner, M. S.
    Marth, C.
    Zeimet, A. G.
    ANNALS OF ONCOLOGY, 2023, 34 : S1045 - S1045
  • [30] Phase II pilot study of caelyx (doxorubicin HCL, pegylated liposomal) in patients with inoperable squamous cell cancer of the head and neck
    Stewart, JSW
    Harrington, KJ
    Harrison, D
    Whittaker, J
    Elliott, P
    ANNALS OF ONCOLOGY, 1998, 9 : 170 - 170
12345